Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

TNFRSF9/4-1BB Antibody #62634

4-1BB   4-1BB ligand receptor   CD137   CD137 antigen   CDw137   homolog of mouse 4-1BB   ILA   induced by lymphocyte activation (ILA)   interleukin-activated receptor. homolog of mouse Ly63   MGC2172   receptor protein 4-1BB   T cell antigen ILA   T-cell antigen 4-1BB homolog   T-cell antigen ILA   TNFRSF9   TNR9   Tumor necrosis factor receptor superfamily member 9   tumor necrosis factor receptor superfamily. member 9  

No. Size Price
62634S 100 µl ( 10 western blots ) ¥3,100.00 现货查询 购买询价
62634 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human, Endogenous 32, 40 Rabbit

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting,

Specificity / Sensitivity

TNFRSF9/4-1BB Antibody recognizes endogenous levels of total TNFRSF9/4-1BB protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln128 of human TNFRSF9/4-1BB protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from activated primary human CD8+ T cells and HDLM-2 cells using TNFRSF9/4-1BB Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from COS-7 cells, mock transfected (-) or transfected with a construct expressing Myc-tagged full-length human TNFRSF9/4-1BB (hTNFRSF9/4-1BB-Myc; +), untreated (-) or treated (+) by PNGase F, using TNFRSF9/4-1BB Antibody (upper), Myc-Tag (9B11) Mouse mAb #2276 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).

Background

TNFRSF9 is a member of the tumor necrosis factor receptor superfamily (1, 2). It is also called 4-1BB or CD137 (1, 2). TNFRSF9/4-1BB is expressed in activated CD4+ and CD8+ T cells, natural killer cells and dendritic cells (2-5) . The ligand TNFSF9/4-1BBL on antigen presenting cells binds to TNFRSF9/4-1BB and costimulates the activation of T cells (5). The binding of agonistic antibodies to TNFRSF9/4-1BB also leads to costimulation for T cell activation (5). Studies have shown the effectiveness of targeting TNFRSF9/4-1BB by its agonistic antibodies in cancer immunotherapy (6).

  1. Sun, Y. et al. (2002) Nat Med 8, 1405-13.
  2. Wilcox, R.A. et al. (2002) J Clin Invest 109, 651-9.
  3. Lin, W. et al. (2008) Blood 112, 699-707.
  4. Wilcox, R.A. et al. (2002) J Immunol 168, 4262-7.
  5. Melero, I. et al. (1997) Nat Med 3, 682-5.
  6. Yonezawa, A. et al. (2015) Clin Cancer Res 21, 3113-20.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Protocols

Companion Products


For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Tween is a registered trademark of ICI Americas, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0

该产品暂无评论!

我要参与评论 :

如要参与评论请先登录网站

还没有网站账户?去注册一下吧

Products

 

Applications